CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		47 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
Revenue
Diagnostic Testing Service	$ 169,230	$ 52,713	$ 644,632
Product Sales	13,440	2,000	21,380
Total Revenue	182,670	54,713	666,012
Cost of Revenue
Diagnostic Testing Service	(47,599)	(3,197)	(83,344)
Product Sales	(18,865)	0	(24,029)
Total Cost of Revenue	(66,464)	(3,197)	(107,373)
Loss on Reduction of Inventory to LCM	0	(23,807)	(121,910)
Gross Profit (Loss)	116,206	27,709	436,729
Selling expenses	(272,575)	(70,435)	(912,451)
Research and Development expenses	(220,192)	(417,990)	(3,777,578)
General and Administrative expenses	(1,564,872)	(601,452)	(7,387,209)
Total operating expenses	(2,057,639)	(1,089,877)	(12,077,238)
Operating Loss	(1,941,433)	(1,062,168)	(11,640,507)
Interest Income	0	863	6,588
Interest Expense	(7)	(1,613)	(39,178)
Net Loss before Income Taxes	(1,941,440)	(1,062,918)	(11,673,097)
Income Taxes	0	0	250
Net Loss	$ (1,941,440)	$ (1,062,917)	$ (11,673,347)
Loss per common share - basic and diluted (in dollars per share)	$ (0.14)	$ (0.09)	$ (1.36)
Weighted average shares outstanding, basic & diluted (in shares)	13,421,119	11,256,867	8,594,390